Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCLNASDAQ:CVACNASDAQ:DAWNNASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$3.67-0.4%$2.47$1.89▼$4.12$1.10B0.363.29 million shs4.78 million shsCVACCureVac$5.37+0.1%$4.10$2.37▼$5.72$1.20B2.49808,892 shs434,903 shsDAWNDay One Biopharmaceuticals$6.37-1.8%$6.81$6.08▼$16.76$645.17M-1.291.24 million shs192,570 shsSOPHSOPHiA GENETICS$3.17+0.6%$2.98$2.58▼$4.92$211.40M177,271 shs1,724 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics+10.51%+17.95%+86.80%+52.07%+31.90%CVACCureVac-0.56%-2.55%+31.05%+88.07%+54.47%DAWNDay One Biopharmaceuticals0.00%-0.31%+3.35%-20.20%-52.11%SOPHSOPHiA GENETICS+3.28%+7.88%+10.53%-14.40%-31.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCLAbCellera Biologics2.1414 of 5 stars3.41.00.00.02.33.30.0CVACCureVac4.5599 of 5 stars4.24.00.04.81.90.01.3DAWNDay One Biopharmaceuticals1.672 of 5 stars3.60.00.00.02.12.50.0SOPHSOPHiA GENETICS1.5633 of 5 stars3.43.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 2.75Moderate Buy$8.33127.38% UpsideCVACCureVac 2.40Hold$9.0067.75% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$30.57380.31% UpsideSOPHSOPHiA GENETICS 2.75Moderate Buy$6.80114.51% UpsideCurrent Analyst Ratings BreakdownLatest SOPH, ABCL, DAWN, and CVAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025CVACCureVacJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $5.006/12/2025CVACCureVacCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform6/12/2025CVACCureVacCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/28/2025CVACCureVacJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$10.005/16/2025ABCLAbCellera BiologicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $10.005/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.004/30/2025CVACCureVacUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.004/16/2025ABCLAbCellera BiologicsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$4.00 ➝ $5.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$28.83M37.94N/AN/A$3.58 per share1.02CVACCureVac$579.18M2.08$0.87 per share6.18$3.36 per share1.60DAWNDay One Biopharmaceuticals$161.92M3.98N/AN/A$4.99 per share1.28SOPHSOPHiA GENETICS$67.17M3.15N/AN/A$1.48 per share2.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$162.86M-$0.56N/AN/AN/A-737.56%-15.98%-12.38%8/5/2025 (Estimated)CVACCureVac$175.50M$0.925.83N/AN/A35.44%30.89%25.54%8/13/2025 (Estimated)DAWNDay One Biopharmaceuticals-$95.50M-$0.71N/AN/AN/A-42.66%-14.98%-13.04%7/8/2025 (Estimated)SOPHSOPHiA GENETICS-$62.49M-$1.00N/AN/AN/A-98.51%-63.47%-40.06%8/5/2025 (Estimated)Latest SOPH, ABCL, DAWN, and CVAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025CVACCureVac-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million5/8/2025Q1 2025ABCLAbCellera Biologics-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million5/6/2025Q1 2025SOPHSOPHiA GENETICS-$0.21-$0.26-$0.05-$0.26$16.76 million$17.78 million4/10/2025Q4 2024CVACCureVac-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A10.1510.15CVACCureVac0.057.657.64DAWNDay One BiopharmaceuticalsN/A10.6210.55SOPHSOPHiA GENETICS0.163.112.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%CVACCureVac17.26%DAWNDay One Biopharmaceuticals87.95%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%CVACCureVacN/ADAWNDay One Biopharmaceuticals6.20%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.42 million212.18 millionOptionableCVACCureVac880224.34 millionN/AOptionableDAWNDay One Biopharmaceuticals60101.36 million95.08 millionOptionableSOPHSOPHiA GENETICS52066.69 million63.43 millionNot OptionableSOPH, ABCL, DAWN, and CVAC HeadlinesRecent News About These CompaniesEnough hype about AI in health—let’s talk about resultsJune 12, 2025 | fastcompany.comM42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and careJune 3, 2025 | zawya.comM42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, careJune 3, 2025 | msn.comM42, partners launch liquid biopsy testing in UAEJune 3, 2025 | tradearabia.comThe Multimodal Imperative: How AI-Driven Technology is Driving Impactful ChangesJune 2, 2025 | fiercepharma.comSOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest UpdateJune 1, 2025 | marketbeat.com'An unusual precedent': Baby Sophia's genetic parents demand new Supreme Court hearingMay 28, 2025 | israelnationalnews.comHigh Court grants custody of IVF baby to adoptive, not biological parentsMay 12, 2025 | msn.comSOPHiA GENETICS First Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 12, 2025 | uk.finance.yahoo.comSupreme Court: IVF mixup baby to remain with birth parentsMay 12, 2025 | israelnationalnews.comSupreme Court upholds decision to keep IVF child with birth mother following embryo mix-upMay 12, 2025 | msn.comSupreme Court rules birth parents of child born in IVF mix-up are legal parentsMay 12, 2025 | msn.comThe Sophia Case: When Parenthood Isn’t Just About GeneticsMay 10, 2025 | blogs.timesofisrael.comSOPHiA GENETICS SA (SOPH) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comSophia Genetics SA (SOPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Improved ...May 7, 2025 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2025 | zacks.comSOPHiA GENETICS Reports First Quarter 2025 ResultsMay 6, 2025 | prnewswire.comSOPHiA GENETICS expands AstraZeneca liquid biopsy testApril 30, 2025 | investing.comSOPHiA GENETICS Expands AstraZeneca Partnership to Advance Liquid Biopsy WorldwideApril 29, 2025 | msn.comSOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACRApril 28, 2025 | prnewswire.comSOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025April 22, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSOPH, ABCL, DAWN, and CVAC Company DescriptionsAbCellera Biologics NASDAQ:ABCL$3.66 -0.03 (-0.68%) As of 11:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.CureVac NASDAQ:CVAC$5.36 +0.01 (+0.09%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Day One Biopharmaceuticals NASDAQ:DAWN$6.36 -0.12 (-1.77%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.SOPHiA GENETICS NASDAQ:SOPH$3.17 +0.02 (+0.63%) As of 11:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Which Analyst-Favorite Drone Stock Will Come Out on Top? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
